JAIME PEREZ DE OTEYZA

Prof. Dr. JAIME PEREZ DE OTEYZA

Hospital Universitario HM Sanchinarro, Madrid, Spain
+1

Research Focus & Metrics

Academic Career Length

40Years (1987-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 January 2016 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
NKNicolaus Kröger
Nicolaus Kröger
CSCarlos Solano
Carlos Solano
CWChristine Wolschke
Christine Wolschke
GBGiuseppe Bandini
Giuseppe Bandini
FPFrancesca Patriarca
Francesca Patriarca
FBFrancesca Bonifazi
Francesca Bonifazi
Chronic graft-versus-host disease (GVHD) is the leading cause of later illness and death after allogeneic hematopoietic stem-cell transplantation. We hypothesized that the inclusion of antihuman T-lymphocyte immune globulin (ATG) in a myeloablative conditioning regimen for patients with acute leukemia would result in a significant reduction in chronic GVHD 2 years after allogeneic peripheral-blood stem-cell transplantation from an HLA-identical sibling. We conducted a prospective, multicenter, open-label, randomized phase 3 study of ATG as part of a conditioning regimen. A total of 168 patients were enrolled at 27 centers. Patients were randomly assigned in a 1:1 ratio to receive ATG or not receive ATG, with stratification according to center and risk of disease. After a median follow-up of 24 months, the cumulative incidence of chronic GVHD was 32.2% (95% confidence interval [CI], 22.1 to 46.7) in the ATG group and 68.7% (95% CI, 58.4 to 80.7) in the non-ATG group (P<0.001). The rate of 2-year relapse-free survival was similar in the ATG group and the non-ATG group (59.4% [95% CI, 47.8 to 69.2] and 64.6% [95% CI, 50.9 to 75.3], respectively; P=0.21), as was the rate of overall survival (74.1% [95% CI, 62.7 to 82.5] and 77.9% [95% CI, 66.1 to 86.1], respectively; P=0.46). There were no significant between-group differences in the rates of relapse, infectious complications, acute GVHD, or adverse events. The rate of a composite end point of chronic GVHD–free and relapse-free survival at 2 years was significantly higher in the ATG group than in the non-ATG group (36.6% vs. 16.8%, P=0.005). The inclusion of ATG resulted in a significantly lower rate of chronic GVHD after allogeneic transplantation than the rate without ATG. The survival rate was similar in the two groups, but the rate of a composite end point of chronic GVHD–free survival and relapse-free survival was higher with ATG. (Funded by the Neovii Biotech and the European Society for Blood and Marrow Transplantation; ClinicalTrials.gov number, NCT00678275.)

9 July 2019 in JAMA
Verified
Journal Article
Open access
PDF file
ABAdriana Bastidas
Adriana Bastidas
JSJAVIER DE LA SERNA
JAVIER DE LA SERNA
MIMohamed El Idrissi
Mohamed El Idrissi
LOLidia Oostvogels
Lidia Oostvogels
PQPhilippe Quittet
Philippe Quittet
FCfor the ZOE-HSCT Study Group Collaborators
for the ZOE-HSCT Study Group Collaborators
Herpes zoster risk increases following autologous hematopoietic stem cell transplantation (HSCT) because of diminished T-cell immunity but declines after 2 to 3 years as immune function improves.1-4 Antiviral prophylaxis is commonly administered to patients after HSCT to prevent such complications,5 but the efficacy depends on adherence to treatment.5-7 Furthermore, the duration of prophylaxis is not standardized,5 and there is a high risk of herpes zoster occurring once prophylaxis has stopped.6,7 Vaccination has the potential to provide long-term protection against herpes zoster, but live attenuated vaccines are contraindicated in immunocompromised individuals because of the risk of varicella resulting from spread of the vaccine strain.8,9

1 September 2019 in The Lancet Infectious Diseases
Verified
Journal Article
Closed access
ADAlemnew F Dagnew
Alemnew F Dagnew
OIOsman Ilhan
Osman Ilhan
WLWon-Sik Lee
Won-Sik Lee
DWDariusz Woszczyk
Dariusz Woszczyk
JKJae-Yong Kwak
Jae-Yong Kwak
Francesco ZajaFrancesco Zaja
Francesco Zaja

1 January 2019 in The Lancet
Verified
Journal Article
Open access
Meletios-Athanasios DimopoulosMeletios-Athanasios Dimopoulos
Meletios-Athanasios Dimopoulos
Francesca GayFrancesca Gay
Francesca Gay
FSFredrik Schjesvold
Fredrik Schjesvold
MBMeral Beksac
Meral Beksac
RHRoman Hajek
Roman Hajek
MJMurali Janakiram
Murali Janakiram
Maintenance therapy following autologous stem cell transplantation (ASCT) can delay disease progression and prolong survival in patients with multiple myeloma. Ixazomib is ideally suited for maintenance therapy given its convenient once-weekly oral dosing and low toxicity profile. In this study, we aimed to determine the safety and efficacy of ixazomib as maintenance therapy following ASCT. The phase 3, double-blind, placebo-controlled TOURMALINE-MM3 study took place in 167 clinical or hospital sites in 30 countries in Europe, the Middle East, Africa, Asia, and North and South America. Eligible participants were adults with a confirmed diagnosis of symptomatic multiple myeloma according to International Myeloma Working Group criteria who had achieved at least a partial response after undergoing standard-of-care induction therapy followed by high-dose melphalan (200 mg/m2) conditioning and single ASCT within 12 months of diagnosis. Patients were randomly assigned in a 3:2 ratio to oral ixazomib or matching placebo on days 1, 8, and 15 in 28-day cycles for 2 years following induction, high-dose therapy, and transplantation. The initial 3 mg dose was increased to 4 mg from cycle 5 if tolerated during cycles 1-4. Randomisation was stratified by induction regimen, pre-induction disease stage, and response post-transplantation. The primary endpoint was progression-free survival (PFS) by intention-to-treat analysis. Safety was assessed in all patients who received at least one dose of ixazomib or placebo, according to treatment actually received. This trial is registered with ClinicalTrials.gov, number NCT02181413, and follow-up is ongoing. Between July 31, 2014, and March 14, 2016, 656 patients were enrolled and randomly assigned to receive ixazomib maintenance therapy (n=395) or placebo (n=261). With a median follow-up of 31 months (IQR 27·3-35·7), we observed a 28% reduction in the risk of progression or death with ixazomib versus placebo (median PFS 26·5 months [95% CI 23·7-33·8] vs 21·3 months [18·0-24·7]; hazard ratio 0·72, 95% CI 0·58-0·89; p=0·0023). No increase in second malignancies was noted with ixazomib therapy (12 [3%] patients) compared with placebo (eight [3%] patients) at the time of this analysis. 108 (27%) of 394 patients in the ixazomib group and 51 (20%) of 259 patients in the placebo group experienced serious adverse events. During the treatment period, one patient died in the ixazomib group and none died in the placebo group. Ixazomib maintenance prolongs PFS and represents an additional option for post-transplant maintenance therapy in patients with newly diagnosed multiple myeloma. Millennium Pharmaceuticals, a wholly owned subsidiary of Takeda Pharmaceutical Company.

1 October 2009 in Haematologica
Verified
Journal Article
Open access
PDF file
JRJose-Maria Ribera
Jose-Maria Ribera
AOAlbert Oriol
Albert Oriol
MGM. Gonzalez
M. Gonzalez
MVMaría-Belén Vidriales
María-Belén Vidriales
SBS. Brunet
S. Brunet
OGOn Behalf Of The Programa Espanol de Tratamiento En Hematologia (Pethema) And Grupo Espanol de Trasplante Hemopoyetico (Geth) Groups
On Behalf Of The Programa Espanol de Tratamiento En Hematologia (Pethema) And Grupo Espanol de Trasplante Hemopoyetico (Geth) Groups
Background Imatinib, given concurrently or alternating with chemotherapy, has improved the response and survival of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) but relapses are still frequent. The aim of this study was to evaluate the feasibility and results of giving imatinib concurrently with intensive chemotherapy, stem cell transplantation and post-transplant imatinib maintenance therapy in patients with newly diagnosed Ph+ ALL. Design and Methods This was a phase II study of patients with newly diagnosed Ph+ ALL given standard chemotherapy, together with imatinib (400 mg/day) until stem cell transplantation, followed by imatinib maintenance therapy for all patients regardless of the molecular status of the disease. Results Of the 30 patients included, 27 (90%) achieved complete remission, one was resistant to treatment and two died during induction therapy. The percentages of major and complete molecular responses were 86% and 21% after induction, and 81% and 65% after consolidation, respectively. Similar results were observed assessing minimal residual disease by flow cytometry. Of the 27 patients who achieved complete remission, 21 underwent stem cell transplantation (16 allogeneic, 5 autologous). Imatinib (400 mg/day) could be administered after transplantation for a median of 3.9 months in 12 patients, although it was interrupted in 10 patients (in 2 cases because of side effects of the drug). Nine patients relapsed, four before and five after stem cell transplantation and eight patients died of transplant-related causes. With a median follow-up of 4.1 years, the probabilities (95% CI) of disease-free and overall survival were 30% (15% to 45%) and 30% (16% to 45%), respectively. Conclusions These results confirm that imatinib is an effective first-line treatment for adult Ph+ ALL when given concurrently with chemotherapy, making stem cell transplantation feasible in a high proportion of patients. However, post-transplantation imatinib administration was limited, mainly because of transplantation-derived complications rather than drug-specific toxicity.

1 March 2006 in Clinical Infectious Diseases
Verified
Journal Article
Closed access
PDF file
BJBranimir Jaksic
Branimir Jaksic
GMGiovanni Martinelli
Giovanni Martinelli
JOJAIME PEREZ DE OTEYZA
JAIME PEREZ DE OTEYZA
CHCharlotte S. Hartman
Charlotte S. Hartman
LLLinda B. Leonard
Linda B. Leonard
KTKenneth J. Tack
Kenneth J. Tack
Background. Gram-positive pathogens can cause serious infections in neutropenic patients with cancer, and vancomycin therapy is often initiated empirically. Linezolid may offer an option for these patients.